Hemophilia Markets Poised for Evolution as Competitive Dynamics between Hemlibra (Roche/Genentech) and Altuviiio (Sanofi) Intensify and Hympavzi (Pfizer) Receives Approval, According to Spherix Global Insights
14. Oktober 2024 12:33 ET
|
Spherix Global Insights
EXTON, PA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Hemophilia, a genetic disorder that impairs blood clotting, affects thousands of people worldwide. The treatment landscape is rapidly evolving, fueled by...
Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)
11. September 2024 06:30 ET
|
Arch Biopartners
TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved the...
[Latest] US Diabetes Devices Market Size/Share Worth USD 19.8 Billion by 2033 at a 7.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
23. Juli 2024 13:30 ET
|
Custom Market Insights
Austin, TX, USA, July 23, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “US Diabetes Devices Market Size, Trends and Insights By Type (Blood Glucose...
[Latest] Global Cardiac Troponin Market Size/Share Worth USD 4.2 Billion by 2033 at a 12.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
09. Juli 2024 04:30 ET
|
Custom Market Insights
Austin, TX, USA, July 09, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cardiac Troponin Market Size, Trends and Insights By Product Type (Cardiac...
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
27. Juni 2024 07:25 ET
|
Arch Biopartners
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that Dalton Pharma Services (Dalton) has completed the...
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
18. Juni 2024 07:35 ET
|
Arch Biopartners
TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary’s Conjoint Health...
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
03. April 2024 07:00 ET
|
Arch Biopartners
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an...
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
02. April 2024 07:26 ET
|
Arch Biopartners
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have...
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
16. Februar 2024 11:24 ET
|
F. Hoffmann-La Roche Ltd
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate...
Uveal Melanoma Market Size & Share to Exceed USD 2.5 Billion by 2034, at CAGR of 5.9%. "Shining a Light on Innovation: Revolutionizing the Uveal Melanoma Market for Brighter Tomorrows" – PMI Leads the Way
01. Februar 2024 20:30 ET
|
PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Uveal Melanoma Market size was valued at about USD 1.5 Billion in 2024 and expected to grow at CAGR of 5.9% to...